This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Please Read Full Prescribing Information, Including Boxed WARNINGS, And Medication Guide. Additional Information Can Be Found At (Photo: AstraZeneca)

AstraZeneca (NYSE: AZN) today introduced Complete the Course, a creative education program to support patients taking BRILINTA ® (ticagrelor). Patients who enroll in the Complete the Course program receive support services across multiple channels to help them stay on their full course of BRILINTA therapy. One important support resource now available is Access My BRILINTA, which provides time-saving prescription access and affordability information to patients and healthcare providers.
Please read full Prescribing Information, including Boxed WARNINGS, and Medication Guide. Additional ...

Please read full Prescribing Information, including Boxed WARNINGS, and Medication Guide. Additional information can be found at (Photo: AstraZeneca)

Complete the Course was created specifically to address patient preference for how they receive information about their medication as they transition from hospital to home. A recent nationwide patient survey showed that patients with ACS value robust, multi-channel communication to learn more about the medication prescribed. The survey was sponsored by AstraZeneca and conducted by Ipsos Public Affairs.

“Cardiologists have a tremendous responsibility to not only provide the best possible care for their patients, but also to ensure that their patients receive complete information about their diagnosis and the importance of adherence to treatment,” stated James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, and Vice President for Global Medical Affairs. “With the combination of the BRILINTA Complete the Course program along with Access My BRILINTA, we are now able to provide a variety of resources to patients with ACS and healthcare providers to help ensure continuity and optimal delivery of care throughout the course of treatment.”

A nationwide patient survey was conducted in 201 patients with ACS. The patients with ACS were adults aged 60 years and older who have suffered a heart attack or have been diagnosed with ACS (including heart attack and chest pain), and have been prescribed some form of medication for treatment of their heart attack.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs